PortalPublikationenInsulin-like growth factor-1 receptor (IGF-1R) in primary an...

Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy.

Standard

Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy. / Friedrich, Reinhard; Hagel, Christian; Bartel-Friedrich, Sylva.

in: ANTICANCER RES, Jahrgang 30, Nr. 5, 5, 01.05.2010, S. 1641-1643.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Friedrich, R, Hagel, C & Bartel-Friedrich, S 2010, 'Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy.', ANTICANCER RES, Jg. 30, Nr. 5, 5, S. 1641-1643. <http://www.ncbi.nlm.nih.gov/pubmed/20592355?dopt=Citation>

APA

Friedrich, R., Hagel, C., & Bartel-Friedrich, S. (2010). Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy. ANTICANCER RES, 30(5), 1641-1643. [5]. http://www.ncbi.nlm.nih.gov/pubmed/20592355?dopt=Citation

Vancouver

Friedrich R, Hagel C, Bartel-Friedrich S. Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy. ANTICANCER RES. 2010 Mai 1;30(5):1641-1643. 5.

Bibtex

@article{185e85002f514b72b279db3fc5d964ab,
title = "Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy.",
abstract = "Insulin-like growth-factor 1 receptor (IGF-1R) plays a key role in the development of cancer and is important for the regulation of tissue growth, predominantly via the growth hormone (GH). Targeting IGF-1R is a current topic of cancer research. The aim of this study was to identify IGF-1R in undifferentiated carcinomas of the head and neck.",
keywords = "Adult, Aged, Carcinoma, Cell Differentiation, Female, Growth Hormone, Head and Neck Neoplasms, Humans, Male, Middle Aged, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, RNA, Viral, Receptor, IGF Type 1",
author = "Reinhard Friedrich and Christian Hagel and Sylva Bartel-Friedrich",
year = "2010",
month = may,
day = "1",
language = "English",
volume = "30",
pages = "1641--1643",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

RIS

TY - JOUR

T1 - Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy.

AU - Friedrich, Reinhard

AU - Hagel, Christian

AU - Bartel-Friedrich, Sylva

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Insulin-like growth-factor 1 receptor (IGF-1R) plays a key role in the development of cancer and is important for the regulation of tissue growth, predominantly via the growth hormone (GH). Targeting IGF-1R is a current topic of cancer research. The aim of this study was to identify IGF-1R in undifferentiated carcinomas of the head and neck.

AB - Insulin-like growth-factor 1 receptor (IGF-1R) plays a key role in the development of cancer and is important for the regulation of tissue growth, predominantly via the growth hormone (GH). Targeting IGF-1R is a current topic of cancer research. The aim of this study was to identify IGF-1R in undifferentiated carcinomas of the head and neck.

KW - Adult

KW - Aged

KW - Carcinoma

KW - Cell Differentiation

KW - Female

KW - Growth Hormone

KW - Head and Neck Neoplasms

KW - Humans

KW - Male

KW - Middle Aged

KW - Nasopharyngeal Neoplasms

KW - Neoplasm Metastasis

KW - Oropharyngeal Neoplasms

KW - RNA, Viral

KW - Receptor, IGF Type 1

M3 - SCORING: Journal article

C2 - 20592355

VL - 30

SP - 1641

EP - 1643

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 5

M1 - 5

ER -